Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)

Completed · Not applicable

Conditions studied: Sleep Apnea Syndromes

In brief

This study is designed to test whether SCN5A mRNA processing is altered in OSA patients, which may contribute to their increased arrhythmic risk, and whether processing of SCN5A mRNA is modulated by CPAP treatment. Specific aims: 1. Compare sodium channel splicing variants in mild, moderate, or severe OSA patients at baseline to at 1 month after CPAP treatment. In addition, the baseline splicing variants of SCN5A in the OSA patients will be compared to an age-matched control group. 2. Hypoxia-associated upstream regulators of SCN5a mRNA splicing, Hypoxia-inducible factor 1-alpha (HIF-1α), RNA Binding Motif Protein 25 (RBM25) and LUC7-Like 3 Pre-MRNA Splicing Factor (LUC7L3), will be examined in OSA patients before and after 1 month of CPAP treatment.

Key facts

Study ID

NCT02725632

Run by

Rhode Island Hospital

People needed

50

Starts

2015-08-01

Expected to finish

2017-03-01

Last updated by the study team

2017-04-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• OSA Eligibility Criteria:
• Age greater than 18 years
• Able to provide informed consent
• New diagnosis of OSA by polysomnogram
• Agree with CPAP treatment
• Control Eligibility Criteria:
• Age greater than 18 years
• Without OSA
• Able to provide informed consent

You may not qualify if…

• Not able to give informed consent due to psychological incapacity
• Chronic use of hypnotics for more than 6 weeks
• Current drug or alcohol addiction
• Rhythm other than sinus at enrollment
• Mandatory and biventricular pacing
• History of heart transplant or left ventricular assist device (LVAD)
• Active use of intravenous vasodilators, vasopressors or inotropes
• Hemodialysis or peritoneal dialysis
• Active infection including bacteremia
• Acute coronary syndrome (ACS) within 6 weeks
• Major trauma or surgery within 6 weeks
• Malignant neoplastic disease on active treatment including chemotherapy and radiation therapy, or life expectancy less than 1 year
• Collagen vascular disease on active treatment including steroids and other immunomodulating drugs
• Systemic steroid use within 6 weeks
• Concomitant use of investigational drug within 6 weeks

Where it is running

• Brown University, Lifespan — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.